[Treatment of non-complicated acute cystitis in women: lomefloxacin versus pefloxacin].

Compare the acceptability of a 3-day regimen with that of a single-dose regimen of fluoroquinolones for the treatment of lower urinary tract infection in women.
A multicentric, randomized open trial was conduced in 595 patients by general practitioners to determine acceptability, efficacy and tolerance of lomefloxacine 400 mg in a once a day dose given for three days compared with a once-a-day 800 mg dose of pefloxacin for the treatment of lower urinary tract infection in women.
The delay to symptom relief was greater than 24 hours in both treatment groups. Symptom relief was observed after treatment onset in only 23% of the patients. Clinical success rate at day 14 was 94.2% for lomefloxacin and 95.7% for pefloxacin. The rates of bacteriological eradication were 90.6% and 92.8% respectively with no significant difference. Adverse events were reported in 27.1% and 33.3% of the patients respectively, digestive disorders (abdominal pain, nausea) and neurosensorial disorders (headache, dizziness) predominated. There was no serious adverse event. The incidence of adverse events related to the treatment according to the investigator was smaller with lomefloxacin (16.1%) than with pefloxacin (23.5%) (p = 0.026).
Acceptability, assessed at day 14, was not significantly different between the two treatment groups. Lomefloxacin was the only antibiotic currently authorized for use in a three-day regimen for the treatment of lower urinary tract infections.
AuthorsJ Guibert, M H Capron, A Giacomino
JournalPresse médicale (Paris, France : 1983) (Presse Med) Vol. 25 Issue 28 Pg. 1271-5 (Sep 28 1996) ISSN: 0755-4982 [Print] FRANCE
Vernacular TitleTraitement de la cystite aiguë non compliquée de la femme: loméfloxacine versus péfloxacine.
PMID8949786 (Publication Type: Clinical Trial, Comparative Study, English Abstract, Journal Article, Multicenter Study, Randomized Controlled Trial)
Chemical References
  • Anti-Infective Agents
  • Fluoroquinolones
  • Quinolones
  • Pefloxacin
  • lomefloxacin
  • Acute Disease
  • Adult
  • Anti-Infective Agents (therapeutic use)
  • Cystitis (drug therapy)
  • Family Practice
  • Female
  • Fluoroquinolones
  • Humans
  • Middle Aged
  • Pefloxacin (therapeutic use)
  • Quinolones (therapeutic use)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!

Choose Username:
Verify Password: